http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2726071-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e18359c3cfa9d82ed4b1cc6403cbc154 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5735 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6863 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6872 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6848 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-573 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-573 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 |
| filingDate | 2019-07-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-07-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fc255532f3c612fa8c783d27d44b3f97 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0026945d12b6b27140ba637aa3f78b54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d207c926b7fd843a9535331cd33eb70e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f0b724d5438d7a16292d2da062b212cd |
| publicationDate | 2020-07-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2726071-C1 |
| titleOfInvention | Method of treatment of isolated systolic arterial hypertension of 1 degree in patients in early period of old and senile age |
| abstract | FIELD: medicine. n SUBSTANCE: invention refers to medicine, namely to therapy, cardiology and clinical pharmacology, and can be used for treating isolated degree 1 systolic arterial hypertension (ISAH) in patients of early period of old age - 65–74 years and senile age - older than 75 years. In all patients with ISAH 1 degree of the above age, molecular diagnostics of blood plasma is performed and the level of expression of cathepsin G, myeloperoxidase, induced hypoxia Ia, hyaluronidase, kininogen-1, pyruvate kinase and subunit of alpha ATP-synthase. In the senile age, the level of expression of apolipoprotein D, a transforming growth factor beta-1, fibulin-5 is additionally determined. If observing the presence of a level of expression of cathepsin G equal to 3.5 ng/ml or more, myeloperoxidase, equal to 23 Un/ml or more, hypoxia of the induced factor Ia equal to 280 pg/ml or more, hyaluronidase equal to 9 mE/l or more, kininogen-1 equal to 85 ng/ml or more, pyruvate kinase equal to 10 Un/ml or more, and subunit of alpha ATP-synthase equal to 60 pg/ml or more, apolipoprotein D, equal to or greater than 30 ng/ml, transforming growth factor beta-1 equal to 900 pg/ml or more, fibulin-5 equal to 250 pg/ml or more, therapy is ensured by prescribing a combination of the blocker to the angiotensin II receptor and the slow calcium channel blocker. n EFFECT: method provides reducing the dose of hypotensive medicines, increasing the effectiveness and safety of the treatment while reducing the economic costs of the pharmacotherapy by using the antihypertensive drugs taking into account the molecular profile of the blood plasma in each patient. n 1 cl, 2 ex |
| priorityDate | 2019-07-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 243.